首页 > 最新文献

Journal of Cardiac Failure最新文献

英文 中文
Reduction of Cardiac Allograft Vasculopathy by PCI: Quantification and Correlation With Outcome After Heart Transplantation 通过 PCI 减少心脏移植血管病变:定量分析及与心脏移植术后结果的相关性
IF 6.7 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-01 DOI: 10.1016/j.cardfail.2024.07.011
MADELEINE ORBAN MD , ANNE KUEHL CandMed , LOUIS PECHMAJOU MD , CHRISTOPH MÜLLER MD , MAROUN SFEIR MD , STEFAN BRUNNER MD , DANIEL BRAUN MD , JOERG HAUSLEITER MD , MARIE-CÉCILE BORIES MD , ANNE-CÉLINE MARTIN MD, PhD , SARAH ULRICH MD , ROBERT DALLA POZZA MD , JULINDA MEHILLI MD , XAVIER JOUVEN MD, PhD , CHRISTIAN HAGL MD , NICOLE KARAM MD, PhD , STEFFEN MASSBERG MD

Background

Percutaneous coronary intervention (PCI) might improve outcome at severe stages of cardiac allograft vasculopathy (CAV) among patients after heart transplantation (HTx). Yet, risk stratification of HTx patients after PCI remains challenging.

Aims

To assess whether the International Society for Heart and Lung Transplantation (ISHLT) CAV classification remains prognostic after PCI and whether risk-stratification models of non-transplanted patients extend to HTx patients with CAV.

Methods

At 2 European academic centers, 203 patients were stratified in cohort 1 (ISHLT CAV1, without PCI, n = 126) or cohort 2 (ISHLT CAV2 and 3, with PCI). At first diagnosis of CAV or first PCI, respectively, ISHLT CAV grades, SYNTAX scores I and II (SXS-I, SXS-II) were used to quantify baseline and residual CAV (rISHLT, rSXS-I, rSXS-II). RSXS-I > 0 defined incomplete revascularization (IR).

Results

SXS-II predicted mortality in cohort 1 (P = 0.004), whereas SXS-I (P = 0.009) and SXS-II (P = 0.002) predicted mortality in cohort 2. Post-PCI, IR (P = 0.004), high rISHLT (P = 0.02) and highest tertile of rSXS-II (P = 0.006) were associated with higher 5-year mortality. In bivariable Cox analysis, baseline SXS-II, IR and rSXS-II remained predictors of 5-year mortality post-PCI. There was a strong inverse relationship between baseline and rSXS-I (r = -0.55; P < 0.001 and r = -0.50; P = 0.003, respectively) regarding the interval to first reintervention.

Conclusion

People with ISHLT CAV classification could apply for risk stratification after PCI. SYNTAX scores could be complemental for risk stratification and individualization of invasive follow-up of HTx patients with CAV.
背景:经皮冠状动脉介入治疗(PCI)可改善心脏移植(HTx)后患者心脏移植物血管病(CAV)严重阶段的预后。目的:评估国际心肺移植学会(ISHLT)的 CAV 分类在 PCI 后是否仍具有预后意义,以及非移植患者的风险分层模型是否适用于患有 CAV 的 HTx 患者:在欧洲的 2 个学术中心,203 名患者被分为队列 1(ISHLT CAV1,无 PCI,n = 126)或队列 2(ISHLT CAV2 和 3,有 PCI)。在首次诊断 CAV 或首次 PCI 时,分别使用 ISHLT CAV 分级、SYNTAX 评分 I 和 II(SXS-I、SXS-II)来量化基线和残余 CAV(rISHLT、rSXS-I、rSXS-II)。RSXS-I>0定义为不完全血管再通(IR):结果:SXS-II可预测队列1的死亡率(P = 0.004),而SXS-I(P = 0.009)和SXS-II(P = 0.002)可预测队列2的死亡率。PCI后,IR(P = 0.004)、高rISHLT(P = 0.02)和rSXS-II的最高三分位数(P = 0.006)与较高的5年死亡率相关。在双变量Cox分析中,基线SXS-II、IR和rSXS-II仍然是PCI术后5年死亡率的预测因素。基线和rSXS-I(分别为r = -0.55;P < 0.001和r = -0.50;P = 0.003)与首次再介入间隔时间之间存在很强的反向关系:结论:ISHLT CAV分级者可在PCI术后进行风险分层。SYNTAX评分可作为CAV HTx患者风险分层和有创随访个体化的补充。
{"title":"Reduction of Cardiac Allograft Vasculopathy by PCI: Quantification and Correlation With Outcome After Heart Transplantation","authors":"MADELEINE ORBAN MD ,&nbsp;ANNE KUEHL CandMed ,&nbsp;LOUIS PECHMAJOU MD ,&nbsp;CHRISTOPH MÜLLER MD ,&nbsp;MAROUN SFEIR MD ,&nbsp;STEFAN BRUNNER MD ,&nbsp;DANIEL BRAUN MD ,&nbsp;JOERG HAUSLEITER MD ,&nbsp;MARIE-CÉCILE BORIES MD ,&nbsp;ANNE-CÉLINE MARTIN MD, PhD ,&nbsp;SARAH ULRICH MD ,&nbsp;ROBERT DALLA POZZA MD ,&nbsp;JULINDA MEHILLI MD ,&nbsp;XAVIER JOUVEN MD, PhD ,&nbsp;CHRISTIAN HAGL MD ,&nbsp;NICOLE KARAM MD, PhD ,&nbsp;STEFFEN MASSBERG MD","doi":"10.1016/j.cardfail.2024.07.011","DOIUrl":"10.1016/j.cardfail.2024.07.011","url":null,"abstract":"<div><h3>Background</h3><div>Percutaneous coronary intervention (PCI) might improve outcome at severe stages of cardiac allograft vasculopathy (CAV) among patients after heart transplantation (HTx). Yet, risk stratification of HTx patients after PCI remains challenging.</div></div><div><h3>Aims</h3><div>To assess whether the International Society for Heart and Lung Transplantation (ISHLT) CAV classification remains prognostic after PCI and whether risk-stratification models of non-transplanted patients extend to HTx patients with CAV.</div></div><div><h3>Methods</h3><div>At 2 European academic centers, 203 patients were stratified in cohort 1 (ISHLT CAV1, without PCI, n = 126) or cohort 2 (ISHLT CAV2 and 3, with PCI). At first diagnosis of CAV or first PCI, respectively, ISHLT CAV grades, SYNTAX scores I and II (SXS-I, SXS-II) were used to quantify baseline and residual CAV (rISHLT, rSXS-I, rSXS-II). RSXS-I &gt; 0 defined incomplete revascularization (IR).</div></div><div><h3>Results</h3><div>SXS-II predicted mortality in cohort 1 (<em>P</em> = 0.004), whereas SXS-I (<em>P</em> = 0.009) and SXS-II (<em>P</em> = 0.002) predicted mortality in cohort 2. Post-PCI, IR (<em>P</em> = 0.004), high rISHLT (<em>P</em> = 0.02) and highest tertile of rSXS-II (<em>P</em> = 0.006) were associated with higher 5-year mortality. In bivariable Cox analysis, baseline SXS-II, IR and rSXS-II remained predictors of 5-year mortality post-PCI. There was a strong inverse relationship between baseline and rSXS-I (r = -0.55; <em>P</em> &lt; 0.001 and r = -0.50; <em>P</em> = 0.003, respectively) regarding the interval to first reintervention.</div></div><div><h3>Conclusion</h3><div>People with ISHLT CAV classification could apply for risk stratification after PCI. SYNTAX scores could be complemental for risk stratification and individualization of invasive follow-up of HTx patients with CAV.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"30 10","pages":"Pages 1222-1230"},"PeriodicalIF":6.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142400398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In Memoriam: Aslan Turer, MD, MHS, MBA (1974–2024) 悼念阿斯兰-图勒,医学博士,医学硕士,工商管理硕士(1974-2024)。
IF 6.7 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-01 DOI: 10.1016/j.cardfail.2024.07.018
Jennifer T. Thibodeau MD, MSCS , Sarah K. Gualano MD, MBA , Lanny Hall MD
{"title":"In Memoriam: Aslan Turer, MD, MHS, MBA (1974–2024)","authors":"Jennifer T. Thibodeau MD, MSCS ,&nbsp;Sarah K. Gualano MD, MBA ,&nbsp;Lanny Hall MD","doi":"10.1016/j.cardfail.2024.07.018","DOIUrl":"10.1016/j.cardfail.2024.07.018","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"30 10","pages":"Pages 1399-1400"},"PeriodicalIF":6.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142400390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Myocardial Revascularization in Heart Failure: A State-of-the-Art Review 心力衰竭的心肌血管重建:最新研究综述
IF 6.7 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-01 DOI: 10.1016/j.cardfail.2024.08.002
MANASI TANNU , ADAM J. NELSON , JENNIFER A. RYMER , W. SCHUYLER JONES MD
Patients with heart failure (HF) and underlying coronary artery disease (CAD) have a substantially higher risk of mortality compared with those with HF from other causes. However, identifying individuals with HF for whom revascularization is likely to improve prognosis is a complex clinical decision. Revascularization is likely beneficial for patients with CAD-predominant symptoms, such as those with acute myocardial infarction or stable ischemic heart disease with refractory angina. However, for patients with HF-predominant symptoms, characterized by dyspnea without acute myocardial infarction or refractory angina, the benefits of revascularization are less clear. This state-of-the-art review summarizes the outcomes, clinical trials, and therapeutic approaches for patients with both CAD and HF, and proposes a therapeutic algorithm to guide the diagnosis and comprehensive workup of these complex patients.
与其他原因导致的心力衰竭(HF)患者相比,患有心力衰竭(HF)并伴有冠状动脉疾病(CAD)的患者的死亡风险要高得多。然而,如何确定对哪些心衰患者进行血管重建可能会改善预后是一项复杂的临床决策。对于以 CAD 为主要症状的患者,如急性心肌梗死或伴有难治性心绞痛的稳定型缺血性心脏病患者,血管重建可能是有益的。然而,对于以呼吸困难为主要症状的心房颤动患者,即没有急性心肌梗死或难治性心绞痛的患者,血管重建的益处并不明显。这篇最新综述总结了同时患有 CAD 和 HF 的患者的治疗结果、临床试验和治疗方法,并提出了一种治疗算法来指导这些复杂患者的诊断和全面检查。
{"title":"Myocardial Revascularization in Heart Failure: A State-of-the-Art Review","authors":"MANASI TANNU ,&nbsp;ADAM J. NELSON ,&nbsp;JENNIFER A. RYMER ,&nbsp;W. SCHUYLER JONES MD","doi":"10.1016/j.cardfail.2024.08.002","DOIUrl":"10.1016/j.cardfail.2024.08.002","url":null,"abstract":"<div><div>Patients with heart failure (HF) and underlying coronary artery disease (CAD) have a substantially higher risk of mortality compared with those with HF from other causes. However, identifying individuals with HF for whom revascularization is likely to improve prognosis is a complex clinical decision. Revascularization is likely beneficial for patients with CAD-predominant symptoms, such as those with acute myocardial infarction or stable ischemic heart disease with refractory angina. However, for patients with HF-predominant symptoms, characterized by dyspnea without acute myocardial infarction or refractory angina, the benefits of revascularization are less clear. This state-of-the-art review summarizes the outcomes, clinical trials, and therapeutic approaches for patients with both CAD and HF, and proposes a therapeutic algorithm to guide the diagnosis and comprehensive workup of these complex patients.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"30 10","pages":"Pages 1330-1342"},"PeriodicalIF":6.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142400393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sex-Based Survival Outcomes in Cardiogenic Shock 心源性休克患者基于性别的生存结果
IF 6.7 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-01 DOI: 10.1016/j.cardfail.2024.06.016
ASHLEY M. DARLINGTON MD , KIRSTEN M. LIPPS MD , BENJAMIN HIBBERT MD, PhD , SHANNON M. DUNLAY MD, MS , GARIMA DAHIYA MD , JACOB C. JENTZER MD

Background

Sex-based disparities have been demonstrated in care delivery for females with cardiogenic shock (CS), including lower use of coronary angiography (CAG), percutaneous intervention (PCI) and mechanical circulatory support (MCS). We evaluated whether sex-based disparities exist and are associated with worse CS outcomes in females.

Methods

We studied a retrospective cohort of 1498 consecutive, unique adult cardiovascular intensive care unit (CICU) admissions with CS from 2007–2018.

Results

Compared to males, females (n = 566, 37.1%) were older (71.7 vs 67.8 years; P < 0.001) but had similar burdens of medical comorbidities. Acute myocardial infarction (AMI) was present in 54.1% of females and 59.1% of males (P = 0.06). There were no sex-based differences in the use of CAG and PCI, but females received temporary MCS less commonly. Specifically, females with non-AMI CS received MCS devices less commonly (17.6% vs 24.4%; P = 0.04). There was no difference in in-hospital or 1-year mortality rates between the sexes. Compared to males, females who received PCI had lower risks of 1-year mortality (unadjusted HR 0.72; P = 0.03), whereas females who received CAG without PCI had higher risks of 1-year mortality (unadjusted HR 1.41; P = 0.02).

Conclusions

No sex-based disparities in mortality due to CS were demonstrated in this large, diverse cohort of patients with CICU admissions. Females who underwent PCI demonstrated lower risks of 1-year mortality, whereas females who underwent CAG without PCI demonstrated higher risks of 1-year mortality compared to males. This may reflect underuse of PCI as a mortality-reducing therapy in females.
背景:已证实女性心源性休克(CS)患者的护理存在性别差异,包括冠状动脉造影术(CAG)、经皮介入治疗(PCI)和机械循环支持(MCS)的使用率较低。我们评估了女性心源性休克患者是否存在性别差异,以及性别差异是否与女性心源性休克患者较差的预后有关:我们对 2007-2018 年间 1498 例连续、独特的成人心血管重症监护病房(CICU)入院 CS 患者进行了回顾性队列研究:与男性相比,女性(n = 566,37.1%)年龄更大(71.7 岁 vs 67.8 岁;P < 0.001),但合并症负担相似。54.1%的女性和59.1%的男性患有急性心肌梗死(AMI)(P = 0.06)。CAG和PCI的使用没有性别差异,但女性接受临时MCS的比例较低。具体而言,非急性心肌梗死 CS 女性接受 MCS 装置的比例较低(17.6% vs 24.4%;P = 0.04)。院内死亡率和1年死亡率在性别上没有差异。与男性相比,接受PCI治疗的女性1年死亡风险较低(未经调整的HR为0.72;P = 0.03),而未接受PCI治疗而接受CAG治疗的女性1年死亡风险较高(未经调整的HR为1.41;P = 0.02):结论:在这一大型、多样化的 CICU 入院患者队列中,CS 导致的死亡率没有性别差异。与男性相比,接受PCI治疗的女性1年死亡风险较低,而接受CAG治疗但不接受PCI治疗的女性1年死亡风险较高。这可能反映了PCI作为一种降低死亡率的疗法在女性患者中使用不足。
{"title":"Sex-Based Survival Outcomes in Cardiogenic Shock","authors":"ASHLEY M. DARLINGTON MD ,&nbsp;KIRSTEN M. LIPPS MD ,&nbsp;BENJAMIN HIBBERT MD, PhD ,&nbsp;SHANNON M. DUNLAY MD, MS ,&nbsp;GARIMA DAHIYA MD ,&nbsp;JACOB C. JENTZER MD","doi":"10.1016/j.cardfail.2024.06.016","DOIUrl":"10.1016/j.cardfail.2024.06.016","url":null,"abstract":"<div><h3>Background</h3><div>Sex-based disparities have been demonstrated in care delivery for females with cardiogenic shock (CS), including lower use of coronary angiography (CAG), percutaneous intervention (PCI) and mechanical circulatory support (MCS). We evaluated whether sex-based disparities exist and are associated with worse CS outcomes in females.</div></div><div><h3>Methods</h3><div>We studied a retrospective cohort of 1498 consecutive, unique adult cardiovascular intensive care unit (CICU) admissions with CS from 2007–2018.</div></div><div><h3>Results</h3><div>Compared to males, females (n = 566, 37.1%) were older (71.7 vs 67.8 years; <em>P</em> &lt; 0.001) but had similar burdens of medical comorbidities. Acute myocardial infarction (AMI) was present in 54.1% of females and 59.1% of males (<em>P</em> = 0.06). There were no sex-based differences in the use of CAG and PCI, but females received temporary MCS less commonly. Specifically, females with non-AMI CS received MCS devices less commonly (17.6% vs 24.4%; <em>P</em> = 0.04). There was no difference in in-hospital or 1-year mortality rates between the sexes. Compared to males, females who received PCI had lower risks of 1-year mortality (unadjusted HR 0.72; <em>P</em> = 0.03), whereas females who received CAG without PCI had higher risks of 1-year mortality (unadjusted HR 1.41; <em>P</em> = 0.02).</div></div><div><h3>Conclusions</h3><div>No sex-based disparities in mortality due to CS were demonstrated in this large, diverse cohort of patients with CICU admissions. Females who underwent PCI demonstrated lower risks of 1-year mortality, whereas females who underwent CAG without PCI demonstrated higher risks of 1-year mortality compared to males. This may reflect underuse of PCI as a mortality-reducing therapy in females.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"30 10","pages":"Pages 1211-1219"},"PeriodicalIF":6.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142400401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Differential Prognostic Impact of Clinical Congestion between Preserved versus Reduced Ejection Fraction in Patients Hospitalized for Acute Decompensated Heart Failure: Findings from the Japanese Kyoto Congestive Heart Failure Registry. 在因急性失代偿性心力衰竭住院的患者中,射血分数保留与减少对临床充血的预后影响存在差异:来自日本 KCHF 登记处的研究结果。
IF 6.7 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-30 DOI: 10.1016/j.cardfail.2024.08.060
Kazuya Nagao, Takao Kato, Hidenori Yaku, Takeshi Morimoto, Kenji Aida, Shiori Kawakami Maruichi, Yasutaka Inuzuka, Yodo Tamaki, Erika Yamamoto, Yusuke Yoshikawa, Takeshi Kitai, Ryoji Taniguchi, Moritake Iguchi, Masashi Kato, Mamoru Takahashi, Toshikazu Jinnai, Takafumi Kawai, Akihiro Komasa, Ryusuke Nishikawa, Yuichi Kawase, Takashi Morinaga, Kanae Su, Mitsunori Kawato, Yuta Seko, Tsukasa Inada, Moriaki Inoko, Mamoru Toyofuku, Yutaka Furukawa, Yoshihisa Nakagawa, Kenji Ando, Kazushige Kadota, Satoshi Shizuta, Yukihito Sato, Koichiro Kuwahara, Neiko Ozasa, Koh Ono, Takeshi Kimura

Background: Most patients hospitalized for heart failure (HF) present with signs of congestion. Prognostic significance of clinical congestion may vary depending on left ventricular ejection fraction (LVEF). This study aims to investigate the prognostic impact of congestion across different LVEF categories.

Methods and results: Composite congestion scores (CCSs; 0-9) derived from the severity of edema, jugular venous pressure, and orthopnea, were analyzed on admission and at discharge in 3787 patients hospitalized for HF (LVEF ≥ 40%: n = 2347, LVEF < 40%: n = 1440). The median admission CCS was 4 in both LVEF strata (P = .64). Adjusted hazard ratios (HRs; 95% confidence interval [CI]) of the moderate (CCS 4-6) and severe congestion [7-9] groups relative to the mild congestion [0-3] group on admission for a composite of all-cause death or HF rehospitalization were 1.20 (1.04-1.39, P = .01) and 1.54 (1.27-1.86, P < .001) in the LVEF ≥ 40% stratum, and 1.20 (1.01-1.44, P = .04) and 0.82 (0.61-1.07, P = .14) in the LVEF < 40% stratum, respectively (Pinteraction< .001). A total of 16% of the patients with LVEF ≥40% and 14% with LVEF <40% had residual congestion (CCS ≥ 1) at discharge, which was associated with a respective adjusted HR of 1.40 (1.18-1.65, P < .001) and 1.25 (0.98-1.58, P = .07) for postdischarge death or HF rehospitalization (Pinteraction = 0.63).

Conclusion: The severity of clinical congestion on admission was associated with adverse clinical outcomes in patients with LVEF ≥ 40%, but not in those with LVEF < 40%. These findings warrant further studies to better understand the detailed profile of congestion across the LVEF spectrum.

背景:大多数因心力衰竭(HF)住院的患者都会出现充血症状。临床充血的预后意义可能因左心室射血分数(LVEF)而异。本研究旨在探讨充血对不同 LVEF 类别预后的影响:对 3787 名因高血压住院的患者(LVEF≥40%:n=2347,LVEF 交互作用=0.63)在入院时和出院时的水肿严重程度、颈静脉压和呼吸暂停得出的综合充血评分(CCS)(0-9)进行了分析:结论:LVEF≥40%的患者入院时临床充血的严重程度与不良临床结果有关,但LVEF≥40%的患者入院时临床充血的严重程度与不良临床结果无关。
{"title":"Differential Prognostic Impact of Clinical Congestion between Preserved versus Reduced Ejection Fraction in Patients Hospitalized for Acute Decompensated Heart Failure: Findings from the Japanese Kyoto Congestive Heart Failure Registry.","authors":"Kazuya Nagao, Takao Kato, Hidenori Yaku, Takeshi Morimoto, Kenji Aida, Shiori Kawakami Maruichi, Yasutaka Inuzuka, Yodo Tamaki, Erika Yamamoto, Yusuke Yoshikawa, Takeshi Kitai, Ryoji Taniguchi, Moritake Iguchi, Masashi Kato, Mamoru Takahashi, Toshikazu Jinnai, Takafumi Kawai, Akihiro Komasa, Ryusuke Nishikawa, Yuichi Kawase, Takashi Morinaga, Kanae Su, Mitsunori Kawato, Yuta Seko, Tsukasa Inada, Moriaki Inoko, Mamoru Toyofuku, Yutaka Furukawa, Yoshihisa Nakagawa, Kenji Ando, Kazushige Kadota, Satoshi Shizuta, Yukihito Sato, Koichiro Kuwahara, Neiko Ozasa, Koh Ono, Takeshi Kimura","doi":"10.1016/j.cardfail.2024.08.060","DOIUrl":"10.1016/j.cardfail.2024.08.060","url":null,"abstract":"<p><strong>Background: </strong>Most patients hospitalized for heart failure (HF) present with signs of congestion. Prognostic significance of clinical congestion may vary depending on left ventricular ejection fraction (LVEF). This study aims to investigate the prognostic impact of congestion across different LVEF categories.</p><p><strong>Methods and results: </strong>Composite congestion scores (CCSs; 0-9) derived from the severity of edema, jugular venous pressure, and orthopnea, were analyzed on admission and at discharge in 3787 patients hospitalized for HF (LVEF ≥ 40%: n = 2347, LVEF < 40%: n = 1440). The median admission CCS was 4 in both LVEF strata (P = .64). Adjusted hazard ratios (HRs; 95% confidence interval [CI]) of the moderate (CCS 4-6) and severe congestion [7-9] groups relative to the mild congestion [0-3] group on admission for a composite of all-cause death or HF rehospitalization were 1.20 (1.04-1.39, P = .01) and 1.54 (1.27-1.86, P < .001) in the LVEF ≥ 40% stratum, and 1.20 (1.01-1.44, P = .04) and 0.82 (0.61-1.07, P = .14) in the LVEF < 40% stratum, respectively (P<sub>interaction</sub>< .001). A total of 16% of the patients with LVEF ≥40% and 14% with LVEF <40% had residual congestion (CCS ≥ 1) at discharge, which was associated with a respective adjusted HR of 1.40 (1.18-1.65, P < .001) and 1.25 (0.98-1.58, P = .07) for postdischarge death or HF rehospitalization (P<sub>interaction</sub> = 0.63).</p><p><strong>Conclusion: </strong>The severity of clinical congestion on admission was associated with adverse clinical outcomes in patients with LVEF ≥ 40%, but not in those with LVEF < 40%. These findings warrant further studies to better understand the detailed profile of congestion across the LVEF spectrum.</p>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Validating the Association Between Composite Metrics of Guideline-Directed Medical Therapy and Clinical Outcomes for Patients With Heart Failure With Reduced Ejection Fraction. 验证射血分数减低型心力衰竭 (HFrEF) 患者的指导性医疗疗法 (GDMT) 综合指标与临床疗效之间的关联。
IF 6.7 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-30 DOI: 10.1016/j.cardfail.2024.08.054
Alexandra Steverson, Jamie Calma, Stephanie Hsiao, Karim Sallam, Anubodh S Varshney, Jessica R Golbus, Paul A Heidenreich, Alexander T Sandhu
{"title":"Validating the Association Between Composite Metrics of Guideline-Directed Medical Therapy and Clinical Outcomes for Patients With Heart Failure With Reduced Ejection Fraction.","authors":"Alexandra Steverson, Jamie Calma, Stephanie Hsiao, Karim Sallam, Anubodh S Varshney, Jessica R Golbus, Paul A Heidenreich, Alexander T Sandhu","doi":"10.1016/j.cardfail.2024.08.054","DOIUrl":"10.1016/j.cardfail.2024.08.054","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of Double-Blind Reviews With Increases in Women as First Authors: An Initial Report From the Journal of Cardiac Failure. 双盲评审与女性第一作者增加的关系:心力衰竭杂志》的初步报告。
IF 6.7 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-29 DOI: 10.1016/j.cardfail.2024.09.004
Ersilia M Defilippis, Elena Donald, Logan Cho, Andrew Sauer, Jennifer Maning, Vanessa Blumer, Alexander Hajduczok, Quentin Youmans, Martha Gulati, Meredith T Hurt, Alayna Humphrey, Nosheen Reza, Robert Mentz, Anuradha Lala

Introduction: Women continue to remain under-represented in academic publishing in the field of cardiology. Some evidence suggests that double-blind peer reviews may mitigate the impact of gender bias. In July 2021, the Journal of Cardiac Failure implemented a process for the conduct of double-blind reviews after previously using single-blind reviews, with the aim of improving author diversity. The purpose of the current study was to examine the association between changes in authorship characteristics and implementation of double-blind reviews.

Methods: Manuscripts were stratified into 3 Eras: March-September 2021 (Era 1: prior to double-blind reviews); March-September 2022 (Era 2); and March-September 2023 (Era 3). All article types except invited editorials were included. Data were abstracted, including names, genders, ranks, and disciplines of the first and senior authors.

Results: A total of 310 manuscripts were included in the analysis. The proportion of women first authors increased from 24% in Era 1 to 34% in Era 2 to 39% in Era 3, while the percentage of women authors serving in a senior authorship role remained fairly stable over time-around 21%-22%. Even after adjusting for region, article type, first-author discipline, and last-author gender, there was an increase in female first authors over time (P = 0.015). Manuscripts with a female senior author were significantly more likely to have a female first author.

Conclusions: Our findings suggest that double-blind peer review may contribute to increased gender diversity of first authors and may highlight areas for future improvement by the Journal and academic publishing in general.

导言:女性在心脏病学学术出版领域的代表性仍然不足。一些证据表明,双盲同行评审可减轻性别偏见的影响。2021 年 7 月,《心力衰竭杂志》实施了双盲审稿流程,此前采用的是单盲审稿,目的是提高作者的多样性。本稿件旨在研究作者特征的变化与实施双盲审稿之间的关联:将稿件分为 3 个时代:方法:将稿件分为 3 个时代:2021 年 3 月至 9 月(时代 1--双盲审稿之前)、2022 年 3 月至 9 月(时代 2)和 2023 年 3 月至 9 月(时代 3)。除特邀社论外,所有文章类型均包括在内。数据摘要包括第一作者和资深作者的姓名、性别、职级和学科:共有 310 篇稿件被纳入分析。女性第一作者的比例从时代1的24%上升到时代2的34%,再上升到时代3的39%,而女性资深作者的比例则一直保持在21-22%左右。即使对地区、文章类型、第一作者学科和最后作者性别进行调整后,女性第一作者的比例也随着时间的推移而增加(p= 0.015)。有女性资深作者的稿件中,女性第一作者的比例明显更高:我们的研究结果表明,双盲同行评审可能有助于提高第一作者的性别多样性,并强调了JCF和学术出版未来需要改进的领域。
{"title":"Association of Double-Blind Reviews With Increases in Women as First Authors: An Initial Report From the Journal of Cardiac Failure.","authors":"Ersilia M Defilippis, Elena Donald, Logan Cho, Andrew Sauer, Jennifer Maning, Vanessa Blumer, Alexander Hajduczok, Quentin Youmans, Martha Gulati, Meredith T Hurt, Alayna Humphrey, Nosheen Reza, Robert Mentz, Anuradha Lala","doi":"10.1016/j.cardfail.2024.09.004","DOIUrl":"10.1016/j.cardfail.2024.09.004","url":null,"abstract":"<p><strong>Introduction: </strong>Women continue to remain under-represented in academic publishing in the field of cardiology. Some evidence suggests that double-blind peer reviews may mitigate the impact of gender bias. In July 2021, the Journal of Cardiac Failure implemented a process for the conduct of double-blind reviews after previously using single-blind reviews, with the aim of improving author diversity. The purpose of the current study was to examine the association between changes in authorship characteristics and implementation of double-blind reviews.</p><p><strong>Methods: </strong>Manuscripts were stratified into 3 Eras: March-September 2021 (Era 1: prior to double-blind reviews); March-September 2022 (Era 2); and March-September 2023 (Era 3). All article types except invited editorials were included. Data were abstracted, including names, genders, ranks, and disciplines of the first and senior authors.</p><p><strong>Results: </strong>A total of 310 manuscripts were included in the analysis. The proportion of women first authors increased from 24% in Era 1 to 34% in Era 2 to 39% in Era 3, while the percentage of women authors serving in a senior authorship role remained fairly stable over time-around 21%-22%. Even after adjusting for region, article type, first-author discipline, and last-author gender, there was an increase in female first authors over time (P = 0.015). Manuscripts with a female senior author were significantly more likely to have a female first author.</p><p><strong>Conclusions: </strong>Our findings suggest that double-blind peer review may contribute to increased gender diversity of first authors and may highlight areas for future improvement by the Journal and academic publishing in general.</p>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2024-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Effects of Burst Steroid Therapy on Short-term Decongestion in Acute Heart Failure Patients With Pro-inflammatory Activation: A Post Hoc Analysis of the CORTAHF Randomized, Open-label, Pilot Trial. 突发类固醇治疗对急性心力衰竭伴有促炎症激活的患者短期解除充血的影响:CORTAHF 随机、开放标签试点试验的事后分析。
IF 6.7 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-29 DOI: 10.1016/j.cardfail.2024.09.002
Jan Biegus, Gad Cotter, Beth A Davison, Yonathan Freund, Adriaan A Voors, Christopher Edwards, Maria Novosadova, Koji Takagi, Hamlet Hayrapetyan, Andranik Mshetsyan, Drambyan Mayranush, Alain Cohen-Solal, Jozine M ter Maaten, Gerasimos Filippatos, Ovidiu Chioncel, Malha Sadoune, Matteo Pagnesi, Tabassome Simon, Marco Metra, Douglas L Mann, Alexandre Mebazaa, Piotr Ponikowski

Background: The effect of steroids on congestion in patients with acute heart failure (AHF) is not known.

Methods and results: Patients with AHF, NT-proBNP levels > 1500 pg/mL and high-sensitivity C-reactive protein (hsCRP) levels > 20 mg/L were randomized to once-daily oral 40 mg prednisone for 7 days or usual care. In this post hoc analysis, congestion score was calculated on the basis of orthopnea, edema and rales (0 reflecting lack of congestion, and 9 maximal congestion) at each time point. Among 100 eligible patients randomized, those assigned to prednisone had a greater improvement in congestion score at day 31 (win odds for the prednisone group compared to usual care at day 31 was 1.77 (95% CI 1.17-2.84; P = 0.0066) in all patients and 2.41 (95% CI 1.37-5.05; P = 0.0016) in patients with IL-6 > 13 pg/mL at baseline. In patients with congestion scores ≥ 7 at baseline, the effects of prednisone therapy on the EQ-5D visual analog scale score were 4.30 (95% CI 0.77-7.83) points at day 7 and 5.40 (0.51-10.29) points at day 31, accompanied by lower heart rate and respiratory rate and higher oxygen saturation compared to usual care.

Conclusions: In patients with AHF and inflammatory activation, 7-day steroid therapy was associated with reduction in signs of congestion up to day 31. These results need confirmation in larger studies examining potential effects of steroids on congestion, diuresis, fluid redistribution and vascular permeability as well as clinical effects in AHF.

背景:类固醇对急性心力衰竭(AHF)患者充血的影响尚不清楚:类固醇对急性心力衰竭(AHF)患者充血的影响尚不清楚:急性心力衰竭、NT-proBNP>1500 pg/mL、高敏C反应蛋白(hsCRP)>20 mg/L的患者被随机分配到每日一次口服40 mg泼尼松或常规治疗,为期7天。在这项事后分析中,每个时间点的充血评分都是根据正呼吸、水肿和啰音计算出来的(0 表示无充血,9 表示最大充血)。在 100 名符合条件的随机患者中,分配到泼尼松组的患者在第 31 天的充血评分改善幅度更大(在所有患者中,泼尼松组在第 31 天与常规治疗相比的胜率为 1.77(95% CI 1.17-2.84;p = 0.0066),而在基线 IL-6>13 pg/mL 的患者中,泼尼松组的胜率为 2.41(95% CI 1.37-5.05;p = 0.0016)。在基线充血评分≥7分的患者中,与常规治疗相比,泼尼松治疗对EQ-5D视觉模拟量表评分的影响在第7天为4.30(95% CI 0.77-7.83)分,在第31天为5.40(0.51-10.29)分,同时心率和呼吸频率降低,血氧饱和度升高:结论:对于患有急性肾功能衰竭和炎症激活的患者,7 天的类固醇治疗与第 31 天充血症状的减轻有关。这些结果需要在更大规模的研究中得到证实,这些研究将考察类固醇对充血、利尿、液体再分布和血管通透性的潜在影响以及对 AHF 的临床效果。
{"title":"The Effects of Burst Steroid Therapy on Short-term Decongestion in Acute Heart Failure Patients With Pro-inflammatory Activation: A Post Hoc Analysis of the CORTAHF Randomized, Open-label, Pilot Trial.","authors":"Jan Biegus, Gad Cotter, Beth A Davison, Yonathan Freund, Adriaan A Voors, Christopher Edwards, Maria Novosadova, Koji Takagi, Hamlet Hayrapetyan, Andranik Mshetsyan, Drambyan Mayranush, Alain Cohen-Solal, Jozine M ter Maaten, Gerasimos Filippatos, Ovidiu Chioncel, Malha Sadoune, Matteo Pagnesi, Tabassome Simon, Marco Metra, Douglas L Mann, Alexandre Mebazaa, Piotr Ponikowski","doi":"10.1016/j.cardfail.2024.09.002","DOIUrl":"10.1016/j.cardfail.2024.09.002","url":null,"abstract":"<p><strong>Background: </strong>The effect of steroids on congestion in patients with acute heart failure (AHF) is not known.</p><p><strong>Methods and results: </strong>Patients with AHF, NT-proBNP levels > 1500 pg/mL and high-sensitivity C-reactive protein (hsCRP) levels > 20 mg/L were randomized to once-daily oral 40 mg prednisone for 7 days or usual care. In this post hoc analysis, congestion score was calculated on the basis of orthopnea, edema and rales (0 reflecting lack of congestion, and 9 maximal congestion) at each time point. Among 100 eligible patients randomized, those assigned to prednisone had a greater improvement in congestion score at day 31 (win odds for the prednisone group compared to usual care at day 31 was 1.77 (95% CI 1.17-2.84; P = 0.0066) in all patients and 2.41 (95% CI 1.37-5.05; P = 0.0016) in patients with IL-6 > 13 pg/mL at baseline. In patients with congestion scores ≥ 7 at baseline, the effects of prednisone therapy on the EQ-5D visual analog scale score were 4.30 (95% CI 0.77-7.83) points at day 7 and 5.40 (0.51-10.29) points at day 31, accompanied by lower heart rate and respiratory rate and higher oxygen saturation compared to usual care.</p><p><strong>Conclusions: </strong>In patients with AHF and inflammatory activation, 7-day steroid therapy was associated with reduction in signs of congestion up to day 31. These results need confirmation in larger studies examining potential effects of steroids on congestion, diuresis, fluid redistribution and vascular permeability as well as clinical effects in AHF.</p>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2024-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety and Feasibility of an Implanted Inferior Vena Cava Sensor for Accurate Volume Assessment: FUTURE-HF2 Trial. 植入式下腔静脉传感器用于精确容量评估的安全性和可行性:FUTURE-HF2 试验。
IF 6.7 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-28 DOI: 10.1016/j.cardfail.2024.09.003
Nir Uriel, Kunjan Bhatt, Rami Kahwash, Thomas R McMinn, Manesh R Patel, Scott Lilly, John R Britton, Louise Corcoran, Barry R Greene, Robyn M Kealy, Annette Kent, William S Sheridan, Ajay J Kirtane, Sanjum S Sethi, Jeremiah P Depta, Scott C Feitell, Gabriel Sayer, Marat Fudim

Background: A novel implantable sensor has been designed to measure the inferior vena cava (IVC) area accurately so as to allow daily monitoring of the IVC area and collapse to predict congestion in heart failure (HF).

Methods: A prospective, multicenter, single-arm, Early Feasibility Study enrolled 15 patients with HF (irrespective of ejection fraction) and with an HF event in the previous 12 months, an elevated NT-proBNP level, and receiving ≥ 40 mg of furosemide equivalent. Primary endpoints included successful deployment without procedure-related (30 days) or sensor-related complications (3 months) and successful data transmission to a secure database (3 months). Accuracy of sensor-derived IVC area, patient adherence, NYHA classification, and KCCQ were assessed from baseline to 3 months. Patient-specific signal alterations were correlated with clinical presentation to guide interventions.

Results: Fifteen patients underwent implantation: 66 ± 12 years; 47% female; 27% with HFpEF, NT-ProBNP levels 2569 (median, IQR: 1674-5187, ng/L; 87% NYHA class III). All patients met the primary safety and effectiveness endpoints. Sensor-derived IVC areas showed excellent agreement with concurrent computed tomography (R2 = 0.99, mean absolute error = 11.15 mm2). Median adherence to daily readings was 98% (IQR: 86%-100%) per patient-month. A significant improvement was seen in NYHA class and a nonsignificant improvement was observed in KCCQ.

Conclusions: Implantation of a novel IVC sensor (FIRE1) was feasible, uncomplicated and safe. Sensor outputs aligned with clinical presentations and improvements in clinical outcomes. Future investigation to establish the IVC sensor remote management of HF is strongly warranted.

背景:设计了一种新型植入式传感器来精确测量下腔静脉(IVC)面积,以便每天监测IVC面积和塌陷情况,预测心力衰竭(HF)的充血情况:一项前瞻性、多中心、单臂、早期可行性研究招募了 15 名在过去 12 个月内发生过心衰事件、NT-proBNP 升高、服用呋塞米等效剂量≥40 毫克的心衰患者(不考虑射血分数)。主要终点包括成功部署,无手术相关并发症(30 天)或传感器相关并发症(3 个月),以及成功将数据传输到安全数据库(3 个月)。从基线到三个月期间,对传感器得出的 IVC 面积、患者依从性、NYHA 分级和 KCCQ 的准确性进行了评估。患者特异性信号改变与临床表现相关联,以指导干预措施:15 名患者接受了植入手术(66±12 岁;47% 女性;27% HFpEF,NT-ProBNP 2569(中位数,IQR:(1674-5187) ng/L;87% NYHA III 级)。所有患者均达到了主要安全性和有效性终点。传感器得出的 IVC 面积与同时进行的 CT 显示出极好的一致性(R2=0.99,平均绝对误差=11.15 mm2)。患者月每日读数的坚持率中位数为 98%(IQR:86-100%)。NYHA分级有明显改善,KCCQ无明显改善:结论:植入新型 IVC 传感器 (FIRE1) 是可行、简便和安全的。传感器的输出结果与临床表现和临床结果的改善相一致。今后,有必要对 IVC 传感器对高血压的远程管理进行研究。
{"title":"Safety and Feasibility of an Implanted Inferior Vena Cava Sensor for Accurate Volume Assessment: FUTURE-HF2 Trial.","authors":"Nir Uriel, Kunjan Bhatt, Rami Kahwash, Thomas R McMinn, Manesh R Patel, Scott Lilly, John R Britton, Louise Corcoran, Barry R Greene, Robyn M Kealy, Annette Kent, William S Sheridan, Ajay J Kirtane, Sanjum S Sethi, Jeremiah P Depta, Scott C Feitell, Gabriel Sayer, Marat Fudim","doi":"10.1016/j.cardfail.2024.09.003","DOIUrl":"10.1016/j.cardfail.2024.09.003","url":null,"abstract":"<p><strong>Background: </strong>A novel implantable sensor has been designed to measure the inferior vena cava (IVC) area accurately so as to allow daily monitoring of the IVC area and collapse to predict congestion in heart failure (HF).</p><p><strong>Methods: </strong>A prospective, multicenter, single-arm, Early Feasibility Study enrolled 15 patients with HF (irrespective of ejection fraction) and with an HF event in the previous 12 months, an elevated NT-proBNP level, and receiving ≥ 40 mg of furosemide equivalent. Primary endpoints included successful deployment without procedure-related (30 days) or sensor-related complications (3 months) and successful data transmission to a secure database (3 months). Accuracy of sensor-derived IVC area, patient adherence, NYHA classification, and KCCQ were assessed from baseline to 3 months. Patient-specific signal alterations were correlated with clinical presentation to guide interventions.</p><p><strong>Results: </strong>Fifteen patients underwent implantation: 66 ± 12 years; 47% female; 27% with HFpEF, NT-ProBNP levels 2569 (median, IQR: 1674-5187, ng/L; 87% NYHA class III). All patients met the primary safety and effectiveness endpoints. Sensor-derived IVC areas showed excellent agreement with concurrent computed tomography (R<sup>2</sup> = 0.99, mean absolute error = 11.15 mm<sup>2</sup>). Median adherence to daily readings was 98% (IQR: 86%-100%) per patient-month. A significant improvement was seen in NYHA class and a nonsignificant improvement was observed in KCCQ.</p><p><strong>Conclusions: </strong>Implantation of a novel IVC sensor (FIRE1) was feasible, uncomplicated and safe. Sensor outputs aligned with clinical presentations and improvements in clinical outcomes. Future investigation to establish the IVC sensor remote management of HF is strongly warranted.</p>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142347365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Psychometric Performance of the Kansas City Cardiomyopathy Questionnaire-12 in Symptomatic Obstructive Hypertrophic Cardiomyopathy. 堪萨斯城心肌病问卷-12 在有症状的阻塞性肥厚型心肌病中的心理测量性能。
IF 6.7 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-28 DOI: 10.1016/j.cardfail.2024.09.010
Andrew J Sauer, Charles F Sherrod, Kensey L Gosch, Suzanne V Arnold, Matthew Reaney, Yue Zhong, Jenny Lam, Kathleen W Wyrwich, John A Spertus

Background: A primary goal of treating patients with obstructive hypertrophic cardiomyopathy (oHCM) is to improve their symptoms, function and quality of life. Although the psychometric properties of the 23-item Kansas City Cardiomyopathy Questionnaire (KCCQ-23) have been described in oHCM, they have not been assessed for the shorter 12-item version (KCCQ-12), which is used increasingly in clinical practice.

Methods and results: Using data from the EXPLORER-HCM trial, the psychometric properties of the KCCQ-12 were evaluated. The KCCQ-12 domain and summary scores had moderate correlations with the most relevant clinical (New York Heart Association class, exercise duration, peak oxygen consumption) and patient-reported measures (EQ-5D-5L visual analog scale, Work Productivity and Activity Impairment [WPAI] questionnaire, and Hypertrophic Cardiomyopathy Symptom Questionnaire [HCMSQ]). KCCQ-12 domain scores had strong internal consistency, and test-retest reliability, demonstrated significant and proportional changes with differing magnitudes of clinical change (assessed by the patients' global impressions of change and the patients' impressions of severity), and they demonstrated close equivalence to the KCCQ-23 scores.

Conclusions: The KCCQ-12 demonstrated good psychometric performance for patients with oHCM, comparable to that of the KCCQ-23, supporting its use in clinical practice to care for patients with oHCM.

背景:治疗阻塞性肥厚型心肌病(oHCM)患者的首要目标是改善其症状、功能和生活质量。虽然23项堪萨斯城心肌病问卷(KCCQ-23)的心理测量特性已在oHCM中进行了描述,但尚未对临床实践中越来越多使用的较短的12项版本(KCCQ-12)进行评估:利用 EXPLORER-HCM 试验的数据,对 KCCQ-12 的心理测量特性进行了评估。KCCQ-12的领域得分和总分与最相关的临床指标(纽约心脏协会分级、运动持续时间、峰值耗氧量)和患者报告指标(EQ-5D-5L视觉模拟量表、工作效率和活动障碍[WPAI]问卷以及肥厚型心肌病症状问卷[HCMSQ])具有中等程度的相关性。KCCQ-12的各领域得分具有很强的内部一致性和测试-再测可靠性,在不同的临床变化幅度(以患者对变化的总体印象和患者对严重程度的印象进行评估)下显示出显著的比例变化,并显示出与KCCQ-23得分接近的等效性:结论:KCCQ-12对oHCM患者具有良好的心理测量性能,与KCCQ-23相当,支持在临床实践中用于oHCM患者的护理。
{"title":"The Psychometric Performance of the Kansas City Cardiomyopathy Questionnaire-12 in Symptomatic Obstructive Hypertrophic Cardiomyopathy.","authors":"Andrew J Sauer, Charles F Sherrod, Kensey L Gosch, Suzanne V Arnold, Matthew Reaney, Yue Zhong, Jenny Lam, Kathleen W Wyrwich, John A Spertus","doi":"10.1016/j.cardfail.2024.09.010","DOIUrl":"10.1016/j.cardfail.2024.09.010","url":null,"abstract":"<p><strong>Background: </strong>A primary goal of treating patients with obstructive hypertrophic cardiomyopathy (oHCM) is to improve their symptoms, function and quality of life. Although the psychometric properties of the 23-item Kansas City Cardiomyopathy Questionnaire (KCCQ-23) have been described in oHCM, they have not been assessed for the shorter 12-item version (KCCQ-12), which is used increasingly in clinical practice.</p><p><strong>Methods and results: </strong>Using data from the EXPLORER-HCM trial, the psychometric properties of the KCCQ-12 were evaluated. The KCCQ-12 domain and summary scores had moderate correlations with the most relevant clinical (New York Heart Association class, exercise duration, peak oxygen consumption) and patient-reported measures (EQ-5D-5L visual analog scale, Work Productivity and Activity Impairment [WPAI] questionnaire, and Hypertrophic Cardiomyopathy Symptom Questionnaire [HCMSQ]). KCCQ-12 domain scores had strong internal consistency, and test-retest reliability, demonstrated significant and proportional changes with differing magnitudes of clinical change (assessed by the patients' global impressions of change and the patients' impressions of severity), and they demonstrated close equivalence to the KCCQ-23 scores.</p><p><strong>Conclusions: </strong>The KCCQ-12 demonstrated good psychometric performance for patients with oHCM, comparable to that of the KCCQ-23, supporting its use in clinical practice to care for patients with oHCM.</p>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142347367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Cardiac Failure
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1